The Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol

Authors

  • Giovanni Battista Dell’Isola Department of Pediatrics, University of Perugia, Perugia, Italy
  • Antonella De Lillo Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Genoa, Italy
  • Martina Giorgia Perinelli Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Genoa, Italy
  • Valeria Ottaviani Department of Pediatrics, University of Perugia, Perugia, Italy
  • Pasquale Striano Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Genoa, Italy
  • Alberto Verrotti Department of Pediatrics, University of Perugia, Perugia, Italy

DOI:

https://doi.org/10.12974/2311-8687.2024.12.08

Keywords:

Glycopyrronium, Sialorrhea, Drooling, Clinical review, Clinical protocol

Abstract

The management of pediatric drooling presents challenges requiring tailored therapeutic approaches. This scoping review examines the efficacy and safety of glycopyrronium in addressing drooling across diverse pediatric populations. Glycopyrronium, an anticholinergic medication, inhibits salivary gland activity, offering promise in managing drooling. Clinical trials and observational studies consistently demonstrate its effectiveness, particularly in children with neurological disabilities like cerebral palsy. Notably, glycopyrronium exhibits efficacy even at lower dosages, emphasizing personalized treatment. However, potential side effects such as dry mouth and vision changes necessitate careful monitoring. Future research should explore predictors of treatment response and include diverse patient populations to optimize management strategies. Overall, glycopyrronium emerges as a valuable therapeutic option for pediatric drooling, improving quality of life for affected children. This review underscores the importance of tailored approaches and highlights the need for further research to enhance outcomes in pediatric drooling management.

References

Miranda-Rius, J.; Brunet-Llobet, L.; Lahor-Soler, E.; Farre, M. Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. Int J Med Sci 2015, 12, 811-824. https://doi.org/10.7150/ijms.12912

Riva, A.; Amadori, E.; Vari, M.S.; Spalice, A.; Belcastro, V.; Viri, M.; Capodiferro, D.; Romeo, A.; Verrotti, A.; Delphi panel experts, g.; et al. Impact and management of drooling in children with neurological disorders: an Italian Delphi consensus. Ital J Pediatr 2022, 48, 118. https://doi.org/10.1186/s13052-022-01312-8

Perinelli, M.; Riva, A.; Federici, C.; Amadori, E.; Viscardi, E.; Terrone, G.; Siri, L.; Verrotti, A.; Striano, P. Comparing Subjective Scales for Rating Drooling: A Pilot, Bicentric, Study. 2022.

Reid, S.M.; Johnson, H.M.; Reddihough, D.S. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol 2010, 52, e23-28. https://doi.org/10.1111/j.1469-8749.2009.03519.x

Mier, R.J.; Bachrach, S.J.; Lakin, R.C.; Barker, T.; Childs, J.; Moran, M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000, 154, 1214-1218. https://doi.org/10.1001/archpedi.154.12.1214

Riva, A.; Federici, C.; Piccolo, G.; Amadori, E.; Verrotti, A.; Striano, P. Exploring treatments for drooling in children with neurological disorders. Expert Rev Neurother 2021, 21, 179-187.https://doi.org/10.1080/14737175.2021.1855146

Reid, S.M.; Westbury, C.; Guzys, A.T.; Reddihough, D.S. Anticholinergic medications for reducing drooling in children with developmental disability. Dev Med Child Neurol 2020, 62, 346-353. https://doi.org/10.1111/dmcn.14350

Jongerius, P.H.; Rotteveel, J.J.; van den Hoogen, F.; Joosten, F.; van Hulst, K.; Gabreels, F.J. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 2001, 160, 509-512. https://doi.org/10.1007/s004310100784

Reed, J.; Mans, C.K.; Brietzke, S.E. Surgical management of drooling: a meta-analysis. Arch Otolaryngol Head Neck Surg 2009, 135, 924-931. https://doi.org/10.1001/archoto.2009.110

Peters, M.; Godfrey, C.; McInerney, P.; Munn, Z.; Trico, A.; Khalil, H. Chapter 11: Scoping Reviews. 2020.

https://doi.org/10.46658/JBIRM-20-01

Pubchem. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/3494 (accessed on 29/02/2024).

Lovardi, E.; De Ioris, M.A.; Lettori, D.; Geremia, C.; Staccioli, S.; Bella, G.D.; Scrocca, R.; Scarselli, A.; Aversa, M.; De Peppo, F.; et al. Glycopyrrolate for drooling in children with medical complexity under three years of age. Ital J Pediatr 2022, 48, 2. https://doi.org/10.1186/s13052-021-01195-1

Jongerius, P.H.; van Tiel, P.; van Limbeek, J.; Gabreëls, F.J.; Rotteveel, J.J. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child 2003, 88, 911-914. https://doi.org/10.1136/adc.88.10.911

Garnock-Jones, K.P. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatric drugs 2012, 14, 263‐269. https://doi.org/10.2165/11208120-000000000-00000

Verdun (QC), P.I. Cuvposa (glycopyrrolate): oral solution 1 mg/5 mL [product monograph]. 2017

Chabicovsky, M.; Winkler, S.; Soeberdt, M.; Kilic, A.; Masur, C.; Abels, C. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol 2019, 370, 154-169. https://doi.org/10.1016/j.taap.2019.03.016

EMA. European Medicines Agency: EMEA/H/C/003883/0000 - Assessment report Sialanar. 2016.

FDA. FDA Approved Drug Products: Cuvposa (Glycopyrronium) Oral Solution.

Blasco, P.A.; Stansbury, J.C. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996, 150, 932-935. https://doi.org/10.1001/archpedi.1996.02170340046009

Stern, L.M. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997, 33, 52-54. https://doi.org/10.1111/j.1440-1754.1997.tb00991.x

Zeller, R.S.; Lee, H.M.; Cavanaugh, P.F.; Davidson, J. Randomized phase iii evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Therapeutics and clinical risk management 2012, 8, 15‐23. https://doi.org/10.2147/TCRM.S26893

Zeller, R.S.; Davidson, J.; Lee, H.M.; Cavanaugh, P.F. Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions. Ther Clin Risk Manag 2012, 8, 25-32. https://doi.org/10.2147/TCRM.S27362

Parr, J.R.; Todhunter, E.; Pennington, L.; Stocken, D.; Cadwgan, J.; O'Hare, A.E.; Tuffrey, C.; Williams, J.; Cole, M.; Colver, A.F. Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2018, 103, 371-376. https://doi.org/10.1136/archdischild-2017-313763

Fayoux, P.; Dinomais, M.; Shaw, H.; Villain, F.; Schwartz, D.; Rondeau, S.; Letellier, G.; Auvin, S. Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: a randomized, double-blind, placebo-controlled trial. Developmental medicine and child neurology 2024. https://doi.org/10.1111/dmcn.15841

Bachrach, S.J.; Walter, R.S.; Trzcinski, K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clinical pediatrics 1998, 37, 485‐490. https://doi.org/10.1177/000992289803700805

Zanon, D.; Tumminelli, C.; Galimberti, A.M.C.; Torelli, L.; Maestro, A.; Barbi, E.; Maximova, N. Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience. Ital J Pediatr 2021, 47, 222. https://doi.org/10.1186/s13052-021-01173-7

Drugs.com. Available online: https://www.drugs.com/sfx/glycopyrrolate-side-effects.html (accessed on 29/02/2024).

Operto, F.F.; Pastorino, G.M.G.; Viggiano, A.; Dell'Isola, G.B.; Dini, G.; Verrotti, A.; Coppola, G. Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review. Curr Neuropharmacol 2023, 21, 1646-1665. https://doi.org/10.2174/1570159X20666220706102708

Downloads

Published

2024-05-15

How to Cite

Dell’Isola, G. B. ., De Lillo, A. ., Perinelli, M. G. ., Ottaviani, V. ., Striano, P. ., & Verrotti, A. . (2024). The Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol. International Journal of Pediatrics and Child Health, 12, 57–65. https://doi.org/10.12974/2311-8687.2024.12.08

Issue

Section

Articles